Synonyms: compound A-1 [WO2022023450]
Compound class:
Synthetic organic
Comment: The chemical structure for flezurafenib was obtained from proposed INN list 130 (Feb. 2024), in which the compound is described as a rapidly accelerated fibrosarcoma (Raf) kinase inhibitor with proposed antineoplastic action. It is one of the Raf inhibitors claimed in patent WO2022023450A1 [1]. Investigation of Jazz Pharmaceuticals' pipeline suggests that flezurafenib may be their oral pan-Raf inhibitor clinical lead JZP815. This lead is being explored for efficacy against solid tumours and haematologic malignancies harbouring oncogenic mutations that activate the RAS-RAF-MAPK pathway. We will update this entry when the structure for flezurafenib or JZP815 is publicly disclosed.
|
|
References |
1. Belfield A, Hawkins N, Glossop SC, Margathe JF, Jones CD, Colletto C. (2022)
Chiral synthesis of fused bicyclic raf inhibitors. Patent number: WO2022023450A1. Assignee: Jazz Pharmaceuticals Ireland Limited. Priority date: 28/07/2021. Publication date: 03/02/2022. |